Literature DB >> 11279527

Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene.

E Arikawa-Hirasawa1, W R Wilcox, A H Le, N Silverman, P Govindraj, J R Hassell, Y Yamada.   

Abstract

Perlecan is a large heparan sulfate (HS) proteoglycan present in all basement membranes and in some other tissues such as cartilage, and is implicated in cell growth and differentiation. Mice lacking the perlecan gene (Hspg2) have a severe chondrodysplasia with dyssegmental ossification of the spine and show radiographic, clinical and chondro-osseous morphology similar to a lethal autosomal recessive disorder in humans termed dyssegmental dysplasia, Silverman-Handmaker type (DDSH; MIM 224410). Here we report a homozygous, 89-bp duplication in exon 34 of HSPG2 in a pair of siblings with DDSH born to consanguineous parents, and heterozygous point mutations in the 5' donor site of intron 52 and in the middle of exon 73 in a third, unrelated patient, causing skipping of the entire exons 52 and 73 of the HSPG2 transcript, respectively. These mutations are predicted to cause a frameshift, resulting in a truncated protein core. The cartilage matrix from these patients stained poorly with antibody specific for perlecan, but there was staining of intracellular inclusion bodies. Biochemically, truncated perlecan was not secreted by the patient fibroblasts, but was degraded to smaller fragments within the cells. Thus, DDSH is caused by a functional null mutation of HSPG2. Our findings demonstrate the critical role of perlecan in cartilage development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11279527     DOI: 10.1038/86941

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  65 in total

Review 1.  Heparan sulfate proteoglycans: intricate molecules with intriguing functions.

Authors:  R V Iozzo
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Genetic disorders of the skeleton: a developmental approach.

Authors:  Uwe Kornak; Stefan Mundlos
Journal:  Am J Hum Genet       Date:  2003-07-31       Impact factor: 11.025

3.  Isoform-specific heparan sulfate binding within the amino-terminal noncollagenous domain of collagen alpha1(XI).

Authors:  Lisa R Warner; Raquel J Brown; Sorcha M C Yingst; Julia Thom Oxford
Journal:  J Biol Chem       Date:  2006-10-24       Impact factor: 5.157

Review 4.  A starting place for the road to function.

Authors:  Jeremiah E Silbert; Geetha Sugumaran
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

5.  A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.

Authors:  Mary C Farach-Carson; Anissa J Brown; Megan Lynam; Jeffrey B Safran; Daniel D Carson
Journal:  Matrix Biol       Date:  2007-10-10       Impact factor: 11.583

Review 6.  Role of perlecan in skeletal development and diseases.

Authors:  John Hassell; Yoshihiko Yamada; Eri Arikawa-Hirasawa
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

7.  Perlecan is required for FGF-2 signaling in the neural stem cell niche.

Authors:  Aurelien Kerever; Frederic Mercier; Risa Nonaka; Susana de Vega; Yuka Oda; Bernard Zalc; Yohei Okada; Nobutaka Hattori; Yoshihiko Yamada; Eri Arikawa-Hirasawa
Journal:  Stem Cell Res       Date:  2013-12-28       Impact factor: 2.020

Review 8.  Biological functions of fucose in mammals.

Authors:  Michael Schneider; Esam Al-Shareffi; Robert S Haltiwanger
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

9.  Knockdown of the pericellular matrix molecule perlecan lowers in situ cell and matrix stiffness in developing cartilage.

Authors:  Xin Xu; Zhiyu Li; Yue Leng; Corey P Neu; Sarah Calve
Journal:  Dev Biol       Date:  2016-08-27       Impact factor: 3.582

10.  Perlecan: an important component of the cartilage pericellular matrix.

Authors:  R Gomes; C Kirn-Safran; M C Farach-Carson; D D Carson
Journal:  J Musculoskelet Neuronal Interact       Date:  2002-12       Impact factor: 2.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.